Exploring kinocardiography for diagnosing aortic valve disease and aneurysms
Impact of Aortic Valve Disease and Thoracic Aortic Aneurysm on Kinocardiographic Signals
Université Libre de Bruxelles · NCT06286358
This study is testing if kinocardiography can help doctors better diagnose aortic valve disease and aortic aneurysms in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Université Libre de Bruxelles (other) |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06286358 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the use of kinocardiography (KCG) in diagnosing aortic valve disease (AVD) and thoracic aortic aneurysm (TAA). Researchers will collect data from patients with varying severities of AVD and TAA, utilizing echocardiography, cardiac MRI, KCG recordings, and phonocardiography. By comparing these patients to a control group without AVD or TAA, the study seeks to understand the effectiveness of KCG in identifying these conditions early. The goal is to enhance diagnostic capabilities and improve patient outcomes through better screening methods.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with severe aortic valve disease or thoracic aortic aneurysm, as well as those with varying severities of aortic stenosis or regurgitation.
Not a fit: Patients with severe rhythm disorders or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of aortic valve disease and thoracic aortic aneurysms, potentially reducing morbidity and mortality.
How similar studies have performed: While kinocardiography is a novel approach, similar studies using advanced imaging techniques have shown promise in improving diagnostic accuracy for cardiovascular conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * "Interventional treatment" group * Adults (\>18 y) * Interventional treatment indication for severe AVD and/or severe TAA, as decided by the Heart Team * "Aortic valve disease of different severities" group * Adults (\>18y) * Aortic stenosis and/or aortic regurgitation and/or bicuspidy of different severities confirmed by echocardiography and/or cardiac MRI * "Control" group : - Adults (\>18 y) appariated with the participants of other groups according to their age, sex, body surface area and LVEF Exclusion Criteria: * Any severe rhythm disorder such as frequent ventricular extrasystoles, atrial tachyarrhythmias * Subject's disabilty to give consent * Subjects suffering from aortic valve disease or thoracic aortic aneurysm will be excluded from the "control" group.
Where this trial is running
Brussels
- Erasme hospital — Brussels, Belgium (RECRUITING)
Study contacts
- Study coordinator: Elza Abdessater, MD
- Email: elza.abdessater@ulb.be
- Phone: 2 555 32 75
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Aortic Valve Disease, Aortic Aneurysm, Aortic stenosis, Aortic regurgitation, Thoracic aortic aneurysm, Kinocardiography